Balancing open source stem cell science with commercialization

Nature Biotechnology

Volumn 29, Issue 2, 2011, Pages 115-116

  Courtney, Aidan ^a   De Sousa, Paul ^a   George, Carol ^b   Laurie, Graeme ^b   Tait, Joyce ^b  

^a Roslin Cells Limited   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINE; HEALTH CARE COST; HUMAN; LETTER; MEDICAL RESEARCH; PATENT; PLURIPOTENT STEM CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; UNITED KINGDOM;

ACCESS TO INFORMATION; BIOTECHNOLOGY; DATABASES, FACTUAL; DRUG INDUSTRY; EMBRYO RESEARCH; GREAT BRITAIN; INTELLECTUAL PROPERTY; STEM CELL RESEARCH;

EID: 79751483464     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1773     Document Type: Letter

References (7)

1. Tait, J. Technol. Anal. Strategic Management 19, 257-277 (2007).
2. Shataway, J., Tait, J. & Wield, D. Technol. Anal. Strategic Management 18, 1-17 (2006).
3. Faulkner, A., Geesink, I., Kent, J. & Fitzpatrick, D. Br. Med. J. 326, 1159-1160 (2003).
4. European commission. Off. J. Eur. Union L324, 121-137 (2007).
5. Us Food and drug Administration. code of Federal regulations. Good Tissue practice for Blood and Biologics companies. Title 21, Vol. 8. (21 cFr 1271) (FdA, Washington, dc, UsA, 1 April 2009). http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/cFrsearch.cfm?cFrpart=1271&showFr=1&s ubpartnode=21:8.0.1.5.52.3.
6. Bergman, K. & Graff, G.D. Nat. Biotechnol. 25, 419-424 (2007).
7. Anonymous. Nature 460, 933 (2009).